Anteris Technologies Global (ASX:AVR) Short Percentage of Float


ASX:AVR Anteris Technologies Global Corp ASX:AVR
50 GF Score
Price A$14.77
! 7 Warning Signs
View Full Analysis

What is Anteris Technologies Global Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:AVR vs INMD, QDEL, SSII: Short Percentage of Float Comparison

For the Medical Devices subindustry, Anteris Technologies Global's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anteris Technologies Global Short Percentage of Float vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Anteris Technologies Global's Short Percentage of Float falls into.


ASX:AVR
50GF Score
Anteris Technologies Global Corp ASX:AVR
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anteris Technologies Global Business Description

Other Exchanges AVR:USA
Address 9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score

Get the complete analysis for ASX:AVR

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$14.77
Price